J. McKenzie

发表

Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study)

S. Hanauer, P. Bampton, J. Reynolds, 2018, Alimentary pharmacology & therapeutics.

Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC).

E. Schmidt, J. Mier, C. Aghajanian, 2020 .

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

S. Pignata, C. Choi, C. Marth, 2021, International Journal of Gynecological Cancer.

20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)

I. Ray-Coquard, D. Lorusso, V. Makker, 2022, Annals of Oncology.

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.

T. Powles, T. Choueiri, B. Melichar, 2023, The Lancet. Oncology.

Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.

C. Porta, T. Powles, R. Motzer, 2023, European urology oncology.

Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.

S. Pignata, I. Ray-Coquard, N. Colombo, 2023, European Journal of Cancer.

1449MO Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study

R. Motzer, B. Melichar, S. Tjulandin, 2022, Annals of Oncology.

Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN+PEMBRO) or sunitinib (SUN) in the CLEAR study

R. Motzer, M. Voss, V. Grünwald, 2022, European Urology Open Science.

Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775

B. Monk, K. Yonemori, I. Ray-Coquard, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

443TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)

S. Bielack, K. Janeway, D. Morgenstern, 2020, Annals of Oncology.

1668TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)

S. Bielack, K. Janeway, D. Morgenstern, 2020 .

Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

C. Porta, R. Motzer, T. Powles, 2023, Journal of Clinical Oncology.

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

C. Porta, R. Motzer, T. Powles, 2023, Frontiers in Oncology.

Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial

T. Choueiri, S. Park, T. Buchler, 2023, International Journal of Cancer.